Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

110.16 3.21 −2.83%
Market cap
$12.3B
P/E
212×
Fwd P/E
139×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
65.69 124.19 236.82 307.36 478.50 266.46 499.25 458.64 471.60 485.46
Total non-current assets
3.06 96.35 74.87 104.95 93.23 157.29 84.18 162.88 368.95 351.19
Total Assets
68.75 220.54 311.69 412.31 571.73 423.76 583.43 621.52 840.55 836.65
Total current liabilities
27.37 29.57 35.57 38.84 47.49 47.54 72.49 104.51 140.77 166.09
Total non-current liabilities
— — 0.24 2.29 0.90 0.41 9.10 10.31 20.19 22.76
Total liabilities
27.37 29.57 35.81 41.13 48.39 47.95 81.59 114.81 160.96 188.85
Common Equity (Total)
41.38 190.97 275.88 371.18 523.34 375.81 501.84 506.71 679.59 647.80
Shareholders Equity (Total)
41.38 190.97 275.88 371.18 523.34 375.81 501.84 506.71 679.59 647.81
Total Debt
14.66 — — 1.90 0.50 0.53 1.14 — 6.11 5.02

Show all line items

In millions of $ except per-share values · columns are period end dates